Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus ILUVIEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus ILUVIEN.
BETAMETHASONE DIPROPIONATE vs ILUVIEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid